<< Exhibitor
<< Press release
The 23rd China International In Vitro Diagnostic Expo by CACLP and its concurrent activities will return from 21–23 March 2026, at the Xiamen International Expo Center in Fujian Province, China.
On June 4 2025, Elsevier officially released the 2024 CiteScore, a key metric used to assess the impact of academic journals. VIEW, jointly sponsored by China Professional Community of Experimental Medicine (CPCEM) and published by John Wiley & Sons, achieved a CiteScore of 14.5 for 2024.
From 18-22 May 2025, Brussels, Belgium, hosted the 26th IFCC-EFLM EUROMEDLAB Congress of Clinical Chemistry and Laboratory Medicine and the 49th Annual Meeting of the Royal Belgian Society of Laboratory Medicine.
The 22nd China International In Vitro Diagnostics Expo by CACLP and the 5th China IVD Supply Chain Expo (CISCE) took place from 22–24 March 2025 in Hangzhou, achieving unprecedented scale and impact.
With just two weeks to go, anticipation is building for the 22nd China International In Vitro Diagnostic Expo by CACLP, the largest and most influential gathering of the IVD industry in China! Taking place 22-24 March 2025, at the Hangzhou Grand Convention & Exhibition Center, CACLP 2025 promises to be a world-class showcase of the latest innovations, professional networking and business opportunities.
The 7th China IVD Distribution Enterprise Forum is set to take place on 23 March 2025, at the Hangzhou Grand Convention and Exhibition Center.
As China’s in vitro diagnostic (IVD) industry continues its rapid development, numerous outstanding enterprises have made remarkable achievements in research and development, production, and market expansion.
Welcome to the 22nd China International In Vitro Diagnostic Expo by CACLP & 5th China IVD Supply Chain Expo!
The 1st National Primary Healthcare Laboratory Forum is a key event focused on strengthening primary healthcare laboratory testing, which plays a vital role in early disease diagnosis and treatment outcomes.
As China’s pet market continues to flourish, with rising pet ownership and increasing per capita spending, the demand for quality veterinary care is rapidly growing.
<< Industry news
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today reported its financial results for the second quarter ended June 30, 2025.
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for its fiscal 2025 third quarter, which ended June 30, 2025.
Personalis reported after the close of the market on Tuesday a 24 percent year-over-year drop in second quarter revenues, missing analyst expectations and prompting the company to slash its full-year sales guidance.
OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its financial results for the three months ended June 30, 2025.
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced solid results for Q2 2025 that exceeded the outlook, and increased the full-year 2025 outlook for net sales growth while reaffirming the adjusted diluted earnings per share (EPS) target that was raised earlier in the year.
QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced financial results for the second quarter ended June 29, 2025.
The most widely used professional and over the counter (OTC) patient self-tests for women’s health are pregnancy and ovulation tests.
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the second quarter ended June 30, 2025.
Roche on Monday announced that its Cobas Respiratory 4-flex test for SARS-CoV-2, influenza A/B, and respiratory syncytial virus has received clearance from the US Food and Drug Administration.
Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.
<< Video showcase
CACLP 2025 onsite - The Convergence of Laboratory Medicine and In Vitro Diagnostics
The 12th China IVD Industry Development Conference (CIIDC)
The 10th China Experimental Medicine Conference (CEMC)
International Laboratory Medicine and In Vitro Diagnostic Forum
The 11th China IVD Industry Development Conference (CIIDC)
The 9th China Experimental Medicine Conference (CEMC)
CACLP 2024 onsite - The Convergence of Laboratory Medicine and In Vitro Diagnostics
CACLP APP is available for download now!
Gentian at CACLP 2023 Onsite
in.vent Diagnostics at CACLP 2023 Onsite
Charming Group at CACLP 2023 Onsite
Dialab at CACLP 2023 Onsite
JTC at CACLP 2023 Onsite
Certest at CACLP 2023 Onsite
Yashraj Biotechnology at CACLP 2023 Onsite
Magtivio at CACLP 2023 Onsite
The 8th China Experimental Medicine Conference (CEMC)
The 10th China IVD Industry Development Conference (CIIDC)
CACLP 2023 onsite - The Convergence of Laboratory Medicine and In Vitro Diagnostics
CACLP's new website is launching!
<< Download centre
CACLP 2025 Post-show Press Release
CACLP 2025 Exhibitor Manual
CACLP 2025 Floor Plan
CACLP 2025 Full Schedule
CACLP & CISCE 2024 Draw Global Attention to Innovations and Collaborations in IVD Industry
CACLP & CISCE to present the latest in IVD with 1300+ Exhibitors and 100+ Concurrent Activities this March in Chongqing.pdf
CACLP & CISCE 2024 - Floor Plan
CACLP & CISCE 2024 - Exhibitor Manual
1200+ Global Exhibitors Confirmed Their Participation on the 21st CACLP and 4th CISCE in Chongqing, March 2024
CACLP & CISCE 2023 Post-show Report
Copyright © 2025 GL events Ruihe (Shanghai) Exhibition Co., Ltd. All Rights Reserved. ( 沪ICP备12004745号-1 )
We deliver the latest IVD news straight to your inbox. Stay in touch with CACLP News.
sign-up for our newsletter today.
To ensure our newsletter hit your inbox, make sure to add @caclp.com to your safe senders list. And, as always, feel free to contact
us with any questions and thanks again for subscribing.
Go back
